Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 19;69(5):e20221163.
doi: 10.1590/1806-9282.20221163. eCollection 2023.

Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals

Jucéli Márcia Hendges Sparvoli  1 , Antonio Cardoso Sparvoli  1 , Afonso Alexandre Pereira  1 , Ana Luisa Machado de Paula  1 , Laís Garcia  1 , Carla Vitola Gonçalves  1
Affiliations

Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals

Jucéli Márcia Hendges Sparvoli et al. Rev Assoc Med Bras (1992). .

Erratum in

  • ERRATUM.
    [No authors listed] [No authors listed] Rev Assoc Med Bras (1992). 2023 Jul 24;69(7):e20221163ERRATUM. doi: 10.1590/1806-9282.20221163ERRATUM. Rev Assoc Med Bras (1992). 2023. PMID: 37493811 Free PMC article.

Abstract

Objective: The objective of this study, carried out at the university hospital of the Federal University of Rio Grande, was to assess whether the treatment of chronic hepatitis C with direct-acting antivirals and the sustained virological response will affect the metabolic influences of the hepatitis C virus and whether these effects will vary according to genotypes and virus load.

Methods: This is an intervention pre-post study, carried out from March 2018 to December 2019, evaluating 273 hepatitis C virus patients treated with direct-acting antivirals. Inclusion criteria included being monoinfected with hepatitis C virus and achieving sustained virological response . Exclusion criteria included the presence of decompensated cirrhosis or co-infected with hepatitis B virus or human immunodeficiency virus. Genotypes, genotype 1 subtypes, and hepatitis C virus viral load were analyzed. Glucose metabolism was evaluated by the Homeostasis Model Assessment-insulin resistance indices: Homeostasis Model Assessment-β, TyG, and HbA1c, measured at the beginning of treatment and in sustained virological response. Statistical analysis with a T test by paired comparison of the means of the variables in the pretreatment and in the sustained virological response.

Results: Homeostasis Model Assessment-insulin resistance analysis: there were no significant differences between pretreatment and sustained virological response. Homeostasis Model Assessment-β analysis: significant increase in genotype 1 patients (p<0.028). TyG index analysis: significant increase in genotype 1b (p<0.017), genotype 3 (p<0.024), and genotype non-1 with low viral load (p<0.039). HbA1c analysis: significant decrease in genotype 3 (p<0.001) and genotype non-1 patients with low viral load (p<0.005).

Conclusion: We detected significant metabolic influences after sustained virological response: impairment in lipid profile and improvements in the glucose metabolism. We found significant differences in genotype dependence, genotype 1 subtypes, and viral load.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: the authors declare there is no conflicts of interest.

Figures

Figure 1
Figure 1. Flowchart of excluded patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, et al. Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals. Can J Gastroenterol Hepatol. 2018;2018:6095097–6095097. doi: 10.1155/2018/6095097. - DOI - PMC - PubMed
    1. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61(3):790–801. doi: 10.1002/hep.27424. - DOI - PMC - PubMed
    1. Chang ML. Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol. 2016;22(4):1461–1476. doi: 10.3748/wjg.v22.i4.1461. - DOI - PMC - PubMed
    1. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012;61(1):128–134. doi: 10.1136/gut.2010.236158. - DOI - PMC - PubMed
    1. Ferreira CT, Silveira TR. Hepatites virais: aspectos da epidemiologia e da prevenção. Rev Bras Epidemiol. 2004;7(4):473–487. doi: 10.1590/S1415-790X2004000400010. - DOI